This CME/CE program is derived from content presented at the Advanced Curriculum for Multiple Sclerosis 2025 Annual Meeting. The expert faculty, Dr. Mark S. Freedman, will first discuss the role of B cells and anti-CD20 as therapeutic targets in the multiple sclerosis treatment landscape. Following, recent clinical trial data will be analyzed, with an emphasis on key differences and practical application strategies for anti-CD20 therapies. At the conclusion of this program, healthcare professionals will be better equipped on how to more effectively treat and manage patients with multiple sclerosis.
Neurologists, MS specialists, fellows, residents, nurses, pharmacists, and other healthcare professionals involved in the management of patients with multiple sclerosis.
Review strategies to assess individualized patient characteristics and disease prognosis to determine the role of CD20 in treatment planning
Develop treatment plans to delay disability and progression in patients with RMS
Review and analyze clinical trial data for CD20 therapeutics to manage patients with RMS
Rationale for the Role of CD20
a. Patient Selection
b. Disability Concerns for Patients with Relapsing MS
c. Biomarkers, Imaging, and Comorbidities
d. Disease Prognosis
Distinguishing CD20 Therapeutics:
a. Pharmacology, Pharmacodynamics, and Route of Administration
b. FDA Guidance (Label)
c. Clinical Trial Review
The Clinical Impact of CD20 Therapeutics on the Long-Term Care of Patients with MS
a. Considerations for Long-Term Safety
b. Effective Shared Decision Making: The Patient’s Perspective
Other Monoclonal Antibodies
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity. Faculty
have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.
| Faculty | Relationship Identified With: |
| Mark S. Freedman, MD
|
Consultant/Advisor: Actelion; Alexion Pharmaceuticals, Inc.; Amgen Inc.; AstraZeneca; Atara Biotherapeutics, Inc.; Bayer AG; Biogen; Celestra Health Systems; EMD Serono Inc.; F. Hoffmann-La Roche Ltd; Find Therapeutics; Horizon Therapeutics; Merck & Co., Inc.; NeuroGenesis; Novartis AG; Sandoz Group AG; Sanofi Genzyme; Sentrex Health Solutions; SetPoint Medical; Teva Pharmaceutical Industries Ltd.
Grant/Research Support: Sanofi Genzyme Speaker’s Bureau: EMD Serono Inc.; F. Hoffmann-La Roche Ltd; Novartis AG |
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC, Nicole McMenamin and Chelsey Simonds hereby state that they do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AcademicCME designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM.
AcademicCME designates this enduring material for a maximum of 0.75 CNE Contact Hours, including 0.75 Pharmacotherapeutic Contact Hours (Provider #P0491).
Participants should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from TG Therapeutics, Inc.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and TG Therapeutics, Inc. do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In order to claim credit, participants must complete the following:
For all CE inquiries or special needs, please contact admin@academiccme.com.
